Quantitative metabolomics identifies prognostic biomarkers associated with NSCLC after chemoradiotherapy
The Analyst · 2026 · 151 (12) · 3531-3540
DOI: 10.1039/d6an00069j ↗Kurz gefasst
Fachartikel in der Zeitschrift The Analyst, 2026. Verfasst von Leirui Yuan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Mass Spectrometry Imaging and Metabolomics (National Ethnic Affairs Commission), Center for Imaging and Systems Biology, College of…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Metabolomics, Biomarkers, Tumor. Die Arbeit nennt 34 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Chinese Academy of Medical Sciences.
Abstract (Originalsprache)
Targeted quantitative metabolomics of pretreatment plasma identified GSH and LPC18:3 as prognostic biomarkers in stage III NSCLC. High GSH predicted better survival, whereas high LPC18:3 indicated a poorer outcome after chemoradiotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Mass Spectrometry Imaging and Metabolomics (National Ethnic Affairs Commission), Center for Imaging and Systems Biology, College of Life and Environmental Sciences, Minzu University of China, Beijing,…
- Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. binan_email@16…
- Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Key Laboratory of Nasopharyng…
- Department of Radiotherapy, The First Hospital of China Medical University, Shenyang, China.
- Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen…
Förderung
- National Key Research and Development Program of China
- Chinese Academy of Medical Sciences
Zitieren
APA
Yuan, L., Wu, L., Qian, M., Li, C., Wang, D., Fang, X., Mao, S., Yang, D., Wang, M., Wang, L., Abliz, Z., Bi, N., & Chen, Y. (2026). Quantitative metabolomics identifies prognostic biomarkers associated with NSCLC after chemoradiotherapy. The Analyst, 151(12), 3531-3540. https://doi.org/10.1039/d6an00069j
Vancouver
Yuan L, Wu L, Qian M, Li C, Wang D, Fang X, et al. Quantitative metabolomics identifies prognostic biomarkers associated with NSCLC after chemoradiotherapy. The Analyst. 2026;151(12):3531-3540. doi:10.1039/d6an00069j
BibTeX
@article{Yuan2026,
author = {Yuan, Leirui and Wu, Linfang and Qian, Mingmin and Li, Chenxi and Wang, Daquan and Fang, Xiang and Mao, Shanlin and Yang, Di and Wang, Minghao and Wang, Luhua and Abliz, Zeper and Bi, Nan and Chen, Yanhua},
title = {Quantitative metabolomics identifies prognostic biomarkers associated with NSCLC after chemoradiotherapy},
journal = {The Analyst},
year = {2026},
volume = {151},
number = {12},
pages = {3531--3540},
doi = {10.1039/d6an00069j}
}
EUVIMED